Skip to content
Home/Companies/Biotech/Engrail Therapeutics
Engrail Therapeutics

Engrail Therapeutics

Biotech·US·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns Engrail Therapeutics?

Engrail Therapeutics is currently owned by Ysios Capital Partners through Ysios BioFund III (2020 vintage), since 2024.

Hand-verified · updated 2026-08-03

Ysios Capital Partners
Investor
Ysios Capital Partners
Ysios BioFund III · 2020 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive
Websitewww.engrail.com

More from Ysios BioFund III

Other portfolio companies in the same fund.

ReproNovo
Active
BiotechCH· 2025
Memo Therapeutics
Memo Therapeutics
Exited 2026
BiotechCH· 2024
to
Neurona Therapeutics
Neurona Therapeutics
Active
BiotechUS· 2024
Kynexis
Kynexis
Active
BiotechNL· 2023
Tagworks Pharmaceuticals
Tagworks Pharmaceuticals
Active
BiotechNL· 2023
Mineralys Therapeutics
Mineralys Therapeutics
Exited 2023
BiotechUS· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Engrail Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Engrail Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue